Evogene Ltd. EVGN
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 6.16M | 3.73M | 5.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 6.16M | 3.73M | 5.72M |
| Cost of Revenue | -- | -- | 3.39M | 3.59M | 1.66M |
| Gross Profit | -- | -- | 2.77M | 143.00K | 4.06M |
| SG&A Expenses | -- | -- | 7.71M | 7.90M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -3.50M |
| Total Operating Expenses | -- | -- | 20.40M | 21.67M | 28.38M |
| Operating Income | -- | -- | -14.24M | -17.94M | -22.66M |
| Income Before Tax | -- | -- | -9.85M | -12.87M | -22.42M |
| Income Tax Expenses | -- | -- | 8.00K | 8.00K | 16.00K |
| Earnings from Continuing Operations | -- | -- | -9.86 | -12.88 | -22.44 |
| Earnings from Discontinued Operations | -- | -- | -6.04M | -3.55M | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 1.64M | 1.99M | 2.16M |
| Net Income | -- | -- | -14.25M | -15.21M | -20.28M |
| EBIT | -- | -- | -14.24M | -17.94M | -22.66M |
| EBITDA | -- | -- | -13.88M | -17.72M | -20.07M |
| EPS Basic | -- | -- | -2.04 | -2.48 | -4.74 |
| Normalized Basic EPS | -- | -- | -- | -- | -1.75 |
| EPS Diluted | -- | -- | -2.04 | -2.48 | -4.74 |
| Normalized Diluted EPS | -- | -- | -- | -- | -1.75 |
| Average Basic Shares Outstanding | -- | -- | 25.31M | 23.39M | 17.33M |
| Average Diluted Shares Outstanding | -- | -- | 25.31M | 23.39M | 17.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |